Next-generation immunotherapies create interconnected CMC, nonclinical, clinical and regulatory challenges. If key decisions around potency, comparability, model relevance, biomarkers and first-in-human strategy are addressed too late, they can result in avoidable development delays and rework. Addressing these considerations early can help identify cross-functional risks, strengthen development strategies and support more informed decision-making throughout the development process.
This webinar brings together regulatory, CMC and nonclinical experts to explore five critical decisions that can strengthen an immunotherapy program from preclinical development through clinical translation and global development. The discussion will examine approaches to establishing credible nonclinical strategies when conventional models have limited relevance, anticipating potency and comparability challenges associated with manufacturing changes and identifying opportunities for early regulatory alignment. Attendees will gain insights into how these considerations can support more effective development planning and reduce potential setbacks as programs advance toward clinical evaluation.
Register for this webinar to learn how early strategic decisions can help reduce risks, minimize delays and strengthen immunotherapy development programs.
Who Should Attend
This webinar will appeal to professionals at emerging, small and mid-sized biotechnology companies involved in immunotherapy development, including:
Chief Medical, Development and Scientific Officers
Heads of Regulatory Affairs, CMC and Clinical Development
Program and Portfolio leaders
Biotechnology Executives preparing for IND/CTA submission, first in-human development, global expansion or pivotal-stage transition
Register free on Xtalks: https://xtalks.com/webinars/de-risking-immunotherapy-development-5-key-early-decisions/
